Pulmonary hypertension is sometimes reversible, but whether it can be reversed depends almost entirely on what’s causing it. Some forms, particularly those driven by treatable underlying conditions like heart valve disease, blood clots, or sleep-disordered breathing, can improve dramatically or resolve completely. Others, like idiopathic pulmonary arterial hypertension, are chronic and progressive, though modern treatments can significantly reduce pressures and improve heart function in many patients.
Pulmonary hypertension is now diagnosed when the average pressure in the pulmonary arteries exceeds 20 mmHg, a threshold lowered from the previous cutoff of 25 mmHg. Understanding which of the five major clinical groups your PH falls into is the single biggest factor in predicting whether reversal is possible.
When PH Is Most Likely to Reverse
The best candidates for full reversal are people whose elevated lung pressures are a downstream effect of another condition that can be fixed. Group 2 PH, caused by left heart disease, is the most common form of pulmonary hypertension overall. When the underlying heart problem is addressed, pulmonary pressures often come down substantially. Repairing or replacing a diseased mitral or aortic valve, for example, removes the backflow of pressure into the lungs. Studies show that nearly half of patients with severe aortic valve narrowing have elevated pulmonary pressures, and correcting the valve can relieve them. In advanced heart failure, mechanical support devices that unload the left ventricle have been shown to persistently reduce filling pressures and trigger reverse remodeling of the pulmonary blood vessels.
Group 3 PH, linked to lung disease or low oxygen levels, also has reversible forms. People living at high altitude can develop PH that resolves when they return to lower elevations. A particularly striking example is obesity hypoventilation syndrome, where the combination of excess weight and impaired breathing drives lung pressures dangerously high. In documented cases, nighttime ventilation therapy has normalized pulmonary artery pressures within as little as six weeks.
Blood Clot-Related PH: A Surgical Option
Group 4, chronic thromboembolic pulmonary hypertension (CTEPH), stands out because it has a potentially curative surgery. In CTEPH, organized blood clots become embedded in the walls of the pulmonary arteries, physically obstructing blood flow. A specialized operation called pulmonary endarterectomy removes this scar-like material and can dramatically lower pressures.
The results, however, are not universally perfect. Roughly 43% of patients still have elevated pressures six months after surgery, defined as a mean pulmonary artery pressure at or above 25 mmHg. That means the majority see meaningful improvement, but a significant portion retain some degree of PH. For patients who aren’t surgical candidates, balloon angioplasty of the pulmonary arteries and targeted medications offer additional options to reduce pressures, though these are management strategies rather than cures.
Congenital Heart Defects and Shunt Closure
Holes in the heart, such as atrial septal defects (ASD), ventricular septal defects (VSD), or a patent ductus arteriosus, allow extra blood to flow into the lungs. Over time, this floods the pulmonary circulation and raises pressures. If caught before the blood vessels have undergone too much permanent damage, closing the defect can reverse PH.
Current guidelines use pulmonary vascular resistance (PVR) to decide whether closure is safe. When PVR is below 3 Wood units, closure is strongly recommended and typically results in pressure normalization. Between 3 and 5 Wood units, closure is still reasonable. Above 5 Wood units, the situation becomes more complex. In some ASD patients, medications can lower resistance enough to make closure feasible, but for those with very high, fixed resistance, particularly Eisenmenger syndrome, closing the defect is actually harmful because the shunt serves as a pressure relief valve for the right side of the heart.
Pulmonary Arterial Hypertension: Managed, Rarely Cured
Group 1 pulmonary arterial hypertension (PAH) is the form most people associate with the disease. It involves progressive thickening and narrowing of the small pulmonary arteries themselves. Idiopathic PAH, heritable forms, and PAH associated with connective tissue diseases or HIV are chronic conditions that currently cannot be fully reversed in most patients.
There is one notable exception within this group. About 12% of people with idiopathic PAH show a positive response to vasoreactivity testing, a procedure during right heart catheterization where a short-acting vasodilator is given to see if the arteries relax. In these patients, the disease is driven primarily by blood vessel constriction rather than permanent structural remodeling. They can be treated with high-dose calcium channel blockers, and among those acute responders, roughly 60% maintain long-term improvement. That translates to about 18% of all idiopathic PAH patients who achieve sustained benefit from this approach, a small but meaningful subset with a significantly better prognosis.
For the remaining majority, PAH requires ongoing combination therapy. Five-year survival rates now reach approximately 87% at specialized centers, a dramatic improvement over historical figures but a reminder that the disease remains serious and life-shortening.
How Treatment Helps the Heart Recover
Even when PH itself isn’t fully reversible, effective treatment can allow the right side of the heart to recover. The right ventricle bears the brunt of pulmonary hypertension. It’s a thin-walled chamber designed for low-pressure work, and when it has to pump against high resistance, it enlarges, thickens, and eventually weakens. This right heart strain is what drives most of the symptoms and determines prognosis.
Research shows that when treatment reduces pulmonary vascular resistance by 40% or more, right ventricular function improves in nearly all patients. In one study, 53 out of 56 patients who achieved that level of resistance reduction showed significant recovery of heart function. Overall, about 60% of PAH patients reach or maintain a right ventricular pumping efficiency above the clinically important threshold of 45%, which is associated with stable long-term function and better survival. Patients with smaller right ventricles at the start of treatment are more likely to reach this benchmark.
This is a critical point: even without fully normalizing pulmonary pressures, reducing them enough to let the right ventricle recover can meaningfully change the course of the disease.
A New Class of Treatment Targeting Vessel Remodeling
Most existing PAH therapies work by relaxing blood vessels, but they don’t address the underlying thickening and overgrowth of cells in the artery walls. A newer medication, sotatercept, works differently. It intercepts growth signals from a family of proteins that drive cell proliferation in the pulmonary arteries. In animal models, this approach actually reversed the structural changes in the vessel walls, restoring their openings. In a phase 3 trial, patients already on background PAH therapy who added sotatercept showed improvements in pulmonary vascular resistance, pulmonary artery pressure, exercise capacity, and blood markers of heart strain.
This represents a shift in how PAH is treated, moving from purely managing symptoms and vessel tone toward addressing the disease process that narrows the arteries in the first place. Whether this translates to true long-term reversal of the disease in humans remains an open question, but early results suggest it can push the needle further than previous therapies alone.
What Determines Your Outlook
The reversibility of pulmonary hypertension comes down to two factors: the cause and the timing. PH caused by a fixable problem (a valve defect, a blood clot, obesity hypoventilation, a heart shunt) has real potential for reversal if treated before the pulmonary arteries undergo permanent structural changes. The longer elevated pressures persist, the more the vessels remodel, and the harder it becomes to undo the damage.
For PAH and other forms where the primary disease is in the pulmonary arteries themselves, “reversible” may not be the right word, but “controllable” increasingly is. Combination drug therapy, newer agents that target vessel remodeling, and careful monitoring of right heart function mean that many patients can achieve significant reductions in pressure, meaningful recovery of heart function, and years of stable disease. The gap between “managed” and “reversed” continues to narrow.